Core Viewpoint - Biogen is set to report its fourth-quarter and full-year 2025 results on February 6, with expectations for sales of $2.21 billion and earnings per share of $1.60, following a previous quarter where earnings exceeded expectations by 23.65% [1][10]. Sales Performance - Sales of Biogen's multiple sclerosis (MS) drugs are anticipated to decline due to generic competition for Tecfidera and biosimilar competition for Tysabri, although new products may offset some of this decline [2]. - The Zacks Consensus Estimate for Tecfidera sales is $120 million, while Tysabri is estimated at $362 million, and Vumerity is expected to rise to $183 million due to increased demand [3]. - U.S. MS sales were better than expected in the first three quarters of 2025, driven by Vumerity, but a steeper decline is expected in the fourth quarter due to increased competition, particularly in Europe [4]. Drug-Specific Insights - Sales of Spinraza are projected to decline to $380 million due to lower demand, while Skyclarys is expected to show sequential growth supported by demand and geographic expansion [5]. - Zurzuvae is likely to continue rising in sales, benefiting from strong patient demand and an expanding prescriber base, with its approval in the EU contributing to growth [6][7]. - Alzheimer's collaboration revenues are expected to rise, driven by Biogen's share of net product revenues from Leqembi, which has shown sequential sales improvement in the U.S. [8][9]. Earnings Surprise and Stock Performance - Biogen has a history of beating earnings estimates, with a four-quarter average surprise of 14.02%, and its stock has increased by 25.9% over the past year, outperforming the industry average of 15.2% [12][13]. - The company's Earnings ESP is currently -2.49%, indicating that the model does not predict an earnings beat this time [15][16].

With a market cap of $88.5 billion, Corning Incorporated (GLW) is a global materials science company that operates across optical communications, display technologies, environmental technologies, specialty materials, and life sciences. It serves industries ranging from telecommunications and consumer electronics to automotive emissions control and laboratory sciences worldwide. Shares of the Corning, New York-based company have significantly surpassed the broader market over the past 52 weeks. GLW stock ...

Core Viewpoint - The market anticipates Cleveland-Cliffs (CLF) to report a year-over-year increase in earnings driven by higher revenues when it releases its results for the quarter ended December 2025 [1] Earnings Expectations - The earnings report is expected on February 9, and positive results could lead to a stock price increase, while negative results may cause a decline [2] - The consensus estimate indicates a quarterly loss of $0.62 per share, reflecting an 8.8% year-over-year change, with revenues projected at $4.62 billion, up 6.8% from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 17.39% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Cleveland-Cliffs is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.81% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, which historically leads to a positive surprise nearly 70% of the time [10] - Cleveland-Cliffs currently holds a Zacks Rank of 3, indicating a reasonable chance of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Cleveland-Cliffs was expected to post a loss of $0.48 per share but actually reported a loss of -$0.45, resulting in a surprise of +6.25% [13] - Over the past four quarters, the company has exceeded consensus EPS estimates twice [14] Conclusion - While an earnings beat may influence stock movement, other factors can also play a significant role in stock performance [15] - Monitoring Earnings ESP and Zacks Rank is crucial for making informed investment decisions ahead of earnings releases [16]

Core Viewpoint - Silvercorp (SVM) is anticipated to report a year-over-year increase in earnings due to higher revenues, with the actual results being a significant factor that could influence its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 9, with a consensus estimate of quarterly earnings at $0.17 per share, reflecting a year-over-year increase of +70% [3]. - Revenues are projected to reach $126.1 million, which is an increase of 50.8% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 22.73% higher in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - However, the Most Accurate Estimate for Silvercorp is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -21.21%, suggesting a bearish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with positive readings being more reliable [8][9]. - Silvercorp currently holds a Zacks Rank of 2, which typically indicates a buy recommendation, but the negative Earnings ESP complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Silvercorp exceeded the consensus EPS estimate by delivering earnings of $0.10 per share against an expectation of $0.09, resulting in a surprise of +11.11% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Conclusion - While Silvercorp is not positioned as a compelling earnings-beat candidate, it is essential for investors to consider various factors beyond earnings results when making investment decisions [14][16].

Core Insights - Revvity (RVTY) reported revenue of $772.06 million for the quarter ended December 2025, marking a year-over-year increase of 5.9% and exceeding the Zacks Consensus Estimate by 0.02% [1] - The company's EPS for the same period was $1.70, up from $1.42 a year ago, representing a surprise of 4.29% over the consensus estimate of $1.63 [1] Financial Performance Metrics - Organic revenue growth for the total was 4%, surpassing the five-analyst average estimate of 2.4% [4] - Organic revenue growth in Life Sciences was reported at 0%, below the estimated 1% by three analysts [4] - Organic revenue growth in Diagnostics was 7%, exceeding the three-analyst average estimate of 3.6% [4] - Net Sales in Life Sciences reached $381.99 million, compared to the average estimate of $376.21 million, reflecting a year-over-year change of +13.6% [4] - Net Sales in Diagnostics were $390.07 million, slightly above the estimated $385.54 million, but showed a year-over-year decline of -0.8% [4] Stock Performance - Revvity's shares have returned +10.9% over the past month, significantly outperforming the Zacks S&P 500 composite's +0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Tyson Foods reported revenue of $14.31 billion for the quarter ended December 2025, marking a year-over-year increase of 5.1% and exceeding the Zacks Consensus Estimate of $14.12 billion by 1.36% [1] - The company's EPS for the same period was $0.97, down from $1.14 a year ago, resulting in an EPS surprise of -3.96% compared to the consensus estimate of $1.01 [1] Financial Performance Metrics - Tyson's stock has returned +12.6% over the past month, outperforming the Zacks S&P 500 composite's +0.7% change, and currently holds a Zacks Rank 3 (Hold) [3] - Year-over-year volume changes showed a decline of 0.3% overall, with specific categories such as Chicken increasing by 3.7% and Beef decreasing by 7.3% [4] - Sales figures for Chicken reached $4.21 billion, surpassing the $4.11 billion estimate, while Beef sales were $5.77 billion, exceeding the $5.64 billion estimate, reflecting increases of +3.6% and +8.2% year-over-year respectively [4] - Prepared Foods sales were reported at $2.67 billion, above the $2.59 billion estimate, indicating an +8.1% year-over-year change [4] - Pork sales were $1.61 billion, slightly below the $1.65 billion estimate, showing a -0.5% year-over-year change [4] - Adjusted Operating Income for Beef was reported at -$143 million, worse than the average estimate of -$94.14 million [4]

Company Overview - ConocoPhillips (COP) has a market capitalization of $128.8 billion and is involved in the exploration, production, transportation, and marketing of crude oil, natural gas, LNG, and natural gas liquids, with operations across multiple regions and a diverse asset portfolio [1] Stock Performance - Over the past 52 weeks, COP shares have increased nearly 3%, underperforming the S&P 500 Index, which has risen 15%. However, on a year-to-date basis, COP shares are up 8.7%, outperforming the S&P 500's 1.5% gain [2] - Compared to the State Street Energy Select Sector SPDR ETF (XLE), which increased by 14.8% over the same period, COP shares have also lagged [3] Earnings and Financial Performance - On November 6, COP shares fell 2.3% due to weaker year-over-year earnings, with Q3 2025 adjusted EPS dropping to $1.61 from $1.78 in Q3 2024. The total average realized price fell 14% year-over-year to $46.44 per BOE, reflecting lower commodity prices impacting profitability despite a 4% increase in production to 2,399 MBOED [6] - For the fiscal year ending December 2025, analysts project a 20.2% year-over-year decline in adjusted EPS to $6.22. Despite this, the company has a strong earnings surprise history, having beaten consensus estimates in the last four quarters [7] Analyst Ratings and Price Targets - Among 28 analysts covering COP, the consensus rating is a "Moderate Buy," consisting of 17 "Strong Buy" ratings, four "Moderate Buy," six "Holds," and one "Moderate Sell" [7] - Susquehanna raised its price target on COP to $115, maintaining a "Positive" rating. The mean price target of $113.37 indicates an 11.9% premium to current price levels, while the highest price target of $132 suggests a potential upside of 30.3% [8]

Core Viewpoint - Colgate-Palmolive Company is a leading global consumer goods firm with a market cap of $72.8 billion, specializing in oral care, personal care, home care, and pet nutrition products, operating in over 200 countries and territories [1] Financial Performance - For fiscal Q4 2025, Colgate reported net sales of $5.23 billion, a 5.8% year-over-year increase, with organic sales up 2.2% despite challenges from exiting private-label pet food [4] - The company's full-year net sales reached a record $20.38 billion, reflecting a 1.4% increase, supported by strong cash flow and significant shareholder returns through dividends and buybacks [4] - Analysts project a 4.6% year-over-year increase in EPS for FY2026, estimating it to be $3.86, with a history of surpassing earnings expectations in the past four quarters [4] Stock Performance - Colgate's shares have underperformed the broader market, declining 14.3% year-to-date, while the S&P 500 Index has increased by 1.4% in the same period [2] - The stock has also lagged behind the State Street Consumer Staples Select Sector SPDR Fund, which rose 4.7% over the past 52 weeks [3] Analyst Ratings - The stock holds a consensus "Moderate Buy" rating, with 21 analysts providing coverage, including nine "Strong Buys," three "Moderate Buys," eight "Holds," and one "Strong Sell" [5] - Recently, JPMorgan Chase analyst raised the price target on Colgate-Palmolive to $93 from $88, reflecting a 5.7% increase and maintaining an "Overweight" rating, indicating confidence in the company's market position and growth prospects [7]

Key Takeaways EFX is set to report 4Q25 results on Feb. 4, with revenues estimated at $1.5B, suggesting 7.8% y/y growth.EFX segments are expected to grow, aided by government revenues, OB3 momentum and a mortgage rebound.EFX EPS is expected at $2.05, implying a 3.3% y/y dip; adjusted EBITDA is likely to rise across key segments.Equifax (EFX) is scheduled to report fourth-quarter 2025 results on Feb. 4, before market open.EFX has a decent earnings surprise history. It has outperformed the Zacks Consensus Est ...

Core Viewpoint - Newell Brands (NWL) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended December 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.18 per share, reflecting a year-over-year increase of +12.5%, while revenues are projected to be $1.89 billion, down 3.3% from the previous year [3] - The stock price may rise if the actual earnings exceed expectations, while a miss could lead to a decline [2] Estimate Revisions - The consensus EPS estimate has been revised down by 26.46% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] - Newell Brands currently has an Earnings ESP of -1.89%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with positive readings being more reliable [9][10] - Newell Brands' combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict an earnings beat [12] Historical Performance - In the last reported quarter, Newell Brands was expected to post earnings of $0.18 per share but delivered $0.17, resulting in a surprise of -5.56% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Conclusion - Newell Brands does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17]